Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
A multinational study reveals that combined exposure to heat waves and substantial landscape fire-sourced air pollution significantly increases cardiovascular mortality, particularly from heart failure, more than either hazard alone, unders
Aficamten, a cardiac myosin inhibitor, demonstrated significant improvements in symptoms, diastolic function, and biomarkers in nonobstructive hypertrophic cardiomyopathy across multiple trials, including the pivotal ACACIA-HCM study.
Decompensated cirrhosis markedly elevates mortality, complications, and costs following cardiac surgery. Optimized risk models and tailored management are essential for improved patient outcomes.
This study evaluates cardiovascular and bone health outcomes after bilateral oophorectomy during benign hysterectomy in postmenopausal women, highlighting increased risk for cardiovascular predisposition but no rise in clinical cardiovascul
Germline and somatic variants in DNMT3A and other CHIP genes elevate pulmonary arterial hypertension risk, including connective tissue disease-associated forms, through pro-inflammatory pathways, highlighting novel biomarkers and therapeuti
The FUSION randomized trial demonstrates that adding CT-derived FFR to coronary CTA significantly reduces unnecessary invasive angiographies without affecting clinical outcomes, cost, or quality of life in stable CAD patients with intermedi
This article reviews the ViVA trial assessing vericiguat, an sGC stimulator, in angina patients with coronary vasospasm but no obstructive coronary artery disease. The study found no significant improvement in vasodilator function or angina
A nationwide observational study reveals tocilizumab use in giant cell arteritis significantly lowers major adverse cardiovascular events compared to methotrexate, highlighting its potential cardiovascular benefits beyond inflammation contr
The VESALIUS-CV trial demonstrates that evolocumab lowers all-cause and cardiovascular mortality in patients with high cardiovascular risk but no prior myocardial infarction or stroke, highlighting its survival benefits in primary preventio
The BRIDGE trial demonstrates that protocol-driven early intensive lipid-lowering therapy significantly improves guideline-recommended LDL-C target attainment in acute coronary syndrome patients, fostering better cardiovascular risk control
TAPIS subgroup analysis reveals that ticagrelor-aspirin combined with thrombolysis may improve outcomes in moderate ischemic stroke patients with multiple acute infarcts, without increasing hemorrhage risk, suggesting infarct pattern as a p
This study reveals that central autonomic network alterations in temporal lobe epilepsy patients contribute to interictal cardiorespiratory dysfunction, potentially increasing SUDEP risk, and highlights connectivity changes post-surgery imp
This study reveals distinct left atrial structural and functional changes associated with obesity in atrial fibrillation patients, highlighting a load-related atrial remodeling that may underlie increased risks of atrial fibrillation and he
Combining left ventricular global longitudinal strain and right atrial reservoir strain greatly improves risk prediction and stratification in pulmonary arterial hypertension, outperforming conventional imaging and clinical models.
This analysis of a randomized trial finds no survival benefit at 15 years for bilateral versus single internal thoracic artery grafting in coronary bypass surgery, highlighting the need for further trials to clarify the multiple arterial gr
A validated polygenic risk score (PRS) independently predicts peripheral artery disease (PAD) and major adverse limb events (MALE) in patients with cardiometabolic disease, adding modest but significant predictive value beyond traditional c
This article reviews a validated clinical risk model predicting arrhythmic events in patients with RYR2-mediated CPVT receiving beta-blockers, facilitating personalized management to reduce life-threatening arrhythmias.
The NATURE trial demonstrates that stent retriever thrombectomy combined with conventional PCI significantly reduces infarct size in STEMI patients with large thrombus burden, without increasing short-term adverse events.
Lepodisiran, an siRNA targeting Lp(a), significantly reduces oxidized phospholipids on apo(a) and apoB, highlighting its therapeutic potential in lowering cardiovascular risk linked to elevated Lp(a).
A novel prime editing screening method enables precise functional classification of LDLR gene variants, enhancing diagnosis and therapeutic strategies for familial hypercholesterolemia.
Open language-specific specialty feeds and department pages.